Very light on the details, sadly. Even WP, typically a good...

Very light on the details, sadly. Even WP, typically a good talker, was finding it hard to make the ends meet on this one.

He knows what is coming from this. Here's how I am seeing it, and thought about before this, that the study was poorly formed and not large enough to draw conclusions. Poor form on the transparency with regards to the rest of the program though. Sounds like the collaboration is with one oncologist somewhere with some patients, not much else.

Not the decisive action one would have desired. I vote (not that it counts for much) to divest the immunotherapies arm ASAP.